Antares Pharma, Inc. (ATRS) Shares Up 7.4%
Antares Pharma, Inc. (NASDAQ:ATRS) shot up 7.4% on Thursday . The company traded as high as $1.92 and last traded at $1.89. 866,696 shares were traded during mid-day trading, a decline of 45% from the average session volume of 1,573,358 shares. The stock had previously closed at $1.76.
A number of research firms have recently weighed in on ATRS. Piper Jaffray Companies set a $3.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Monday, October 23rd. HC Wainwright set a $5.00 target price on Antares Pharma and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Vetr raised Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research note on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $3.84.
The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.
Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.01 million. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. equities analysts anticipate that Antares Pharma, Inc. will post -0.11 earnings per share for the current fiscal year.
In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. Corporate insiders own 11.60% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Capital Advantage Inc. bought a new position in Antares Pharma during the 3rd quarter valued at approximately $110,000. Alliancebernstein L.P. bought a new position in Antares Pharma during the 2nd quarter valued at approximately $119,000. Legal & General Group Plc bought a new position in Antares Pharma during the 2nd quarter valued at approximately $120,000. MML Investors Services LLC raised its position in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Credit Suisse AG bought a new position in Antares Pharma during the 1st quarter valued at approximately $146,000. 36.84% of the stock is owned by institutional investors and hedge funds.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.